Nasal Polyps Market Outlook 2024-2034:
The nasal polyps market size reached a value of USD 68.6 Million in 2023. Looking forward, the market is expected to reach USD 109.0 Million by 2034, exhibiting a growth rate (CAGR) of 4.3% during 2024-2034.
The market is driven by the increasing adoption of biologic therapies, such as dupilumab (Dupixent), the shift towards biologics, and the growing emphasis on minimally invasive surgical techniques. Additionally, there is an increasing focus on personalized medicine. Genetic and biomarker research is helping to identify patient subgroups that are more likely to respond to specific treatments, allowing for more tailored and effective management strategies.
Increasing Adoption of Biologic Therapies: Driving the Nasal Polyps Market
The nasal polyps market is experiencing a paradigm shift with the increasing adoption of biologic therapies. Biologics are advanced treatments derived from living organisms and are designed to target specific components of the immune system. This trend is primarily driven by the efficacy of these therapies in managing chronic rhinosinusitis with nasal polyps (CRSwNP), particularly in patients who do not respond adequately to conventional treatments such as corticosteroids. Moreover, one of the most significant biologics in this space is dupilumab (Dupixent), an interleukin-4 receptor alpha antagonist that inhibits the signaling of interleukins 4 and 13, key drivers of inflammation in CRSwNP. Clinical trials have demonstrated that dupilumab significantly reduces nasal polyp size, improves nasal congestion, and enhances overall quality of life. According to a study published in the Journal of Allergy and Clinical Immunology, patients treated with dupilumab showed a 57% reduction in nasal polyp score compared to placebo, along with marked improvements in symptoms and sinus opacification.
Request a PDF Sample Report: https://www.imarcgroup.com/nasal-polyps-market/requestsample
Additionally, the adoption of biologics is also fueled by their ability to reduce the need for surgery. Traditional treatments often involve repeated surgeries to remove polyps, which can be invasive and carry risks of complications. Biologics, by addressing the underlying inflammatory pathways, offer a non-surgical option that can maintain long-term control of symptoms. This is particularly important for patients with severe or recurrent polyps who face multiple surgeries throughout their lifetime. Furthermore, the approval of biologics by regulatory bodies like the FDA and EMA has provided a strong endorsement of their safety and efficacy. The FDA's approval of dupilumab for CRSwNP in 2019 marked a significant milestone, expanding the therapeutic options available to patients. This regulatory support has encouraged healthcare providers to incorporate biologics into their treatment regimens, further driving their adoption.
Advances in Minimally Invasive Surgical Techniques: Contributing to Market Expansion
The nasal polyps market is also witnessing significant advancements in minimally invasive surgical techniques. These innovations are reshaping the way nasal polyps are managed, offering patients less invasive options with shorter recovery times and fewer complications. Endoscopic sinus surgery (ESS) has become the gold standard for surgical intervention in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who do not respond to medical therapy. ESS involves the use of an endoscope to visualize the nasal passages and sinuses, allowing surgeons to remove polyps and other obstructions with high precision. The evolution of ESS has been marked by several technological advancements. High-definition cameras and advanced imaging systems provide surgeons with clear, detailed views of the sinus anatomy, enabling more accurate and effective surgeries. According to a review in the American Journal of Rhinology & Allergy, these technological improvements have significantly enhanced surgical outcomes, reducing the risk of complications and improving patient satisfaction.
Additionally, one of the notable innovations in minimally invasive surgery is balloon sinuplasty. This technique involves the insertion of a small balloon catheter into the sinus passage, which is then inflated to dilate the sinus openings. Balloon sinuplasty is particularly beneficial for patients with mild to moderate disease, as it is less invasive than traditional ESS and can be performed under local anesthesia. Studies have shown that balloon sinuplasty effectively improves sinus drainage and reduces symptoms with minimal discomfort and downtime. Another emerging trend is the integration of navigation systems and robotics in sinus surgery. Image-guided surgery (IGS) systems use preoperative CT scans to create a three-dimensional map of the patient's sinus anatomy, which guides the surgeon during the procedure. This technology enhances precision, especially in complex cases or in patients with distorted anatomy due to previous surgeries. Robotic-assisted surgery is also being explored to provide even greater control and accuracy. These innovations are expected to further reduce complications and improve surgical outcomes.
Emphasis on Personalized Medicine and Biomarker Research:
Personalized medicine and biomarker research are increasingly shaping the landscape of the nasal polyps market. This trend is driven by the recognition that chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous condition with diverse underlying mechanisms. Understanding the specific pathophysiological pathways involved in each patient can lead to more targeted and effective treatments, improving patient outcomes and reducing unnecessary interventions. Moreover, biomarker research has been instrumental in identifying distinct endotypes of CRSwNP. These endotypes are characterized by different inflammatory profiles, such as eosinophilic and non-eosinophilic types. Eosinophilic CRSwNP, which is marked by high levels of eosinophils, responds well to biologic therapies like dupilumab and mepolizumab that target specific cytokines involved in eosinophilic inflammation. By contrast, non-eosinophilic CRSwNP may require different therapeutic approaches.
Apart from this, advancements in diagnostic technologies are facilitating the identification of these biomarkers in clinical practice. Non-invasive tests that measure biomarker levels in nasal secretions or blood are becoming more accessible. For example, periostin, an extracellular matrix protein, has been identified as a potential biomarker for eosinophilic inflammation in CRSwNP. Elevated levels of periostin in nasal secretions can help clinicians identify patients who are likely to benefit from specific biologic therapies. Furthermore, the integration of biomarker research into clinical practice is enabling personalized treatment plans. Patients can be stratified based on their biomarker profiles, allowing for tailored therapy that targets the specific inflammatory pathways involved in their disease. This personalized approach not only enhances the efficacy of treatment but also minimizes adverse effects by avoiding unnecessary or ineffective therapies. Besides this, clinical trials are increasingly incorporating biomarker stratification to identify patient subgroups most likely to benefit from specific treatments. This approach is enhancing the precision of clinical research and accelerating the development of targeted therapies. For instance, trials investigating biologics for CRSwNP often include biomarker analysis to determine which patients exhibit the best response. Such stratified trials provide valuable insights into the efficacy and safety of new treatments across different patient populations.
Buy Full Report: https://www.imarcgroup.com/checkout?id=7725&method=587
Leading Companies in the Nasal Polyps Market:
The market research report by IMARC encompasses a comprehensive analysis of the competitive landscape in the market. Across the global nasal polyps market, several leading companies are at the forefront due to their significant contributions to the development and approval of new treatments. Some of the major players include Sanofi, Regeneron Pharmaceuticals, and GlaxoSmithKline (GSK). These companies lead the market through their innovative products, extensive research and development, and successful navigation of regulatory approvals.
Sanofi is a major player in the nasal polyps market, primarily due to its biologic therapy, dupilumab (Dupixent). Sanofi reported a robust second quarter in 2024, with a 29.2% increase in Dupixent sales, reaching €3,303 million. Dupixent's strong performance is pivotal in Sanofi's projected €13 billion target for 2024. The drug continues to gain traction across multiple indications, including chronic rhinosinusitis with nasal polyps (CRSwNP).
Regeneron Pharmaceuticals, in collaboration with Sanofi, announced positive outcomes from two pivotal Phase 3 trials, SINUS-24 and SINUS-52. These studies demonstrated that Dupixent significantly reduced nasal polyp size, nasal congestion severity, and the need for systemic corticosteroids and surgery. These findings were presented at the Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in San Francisco, highlighting Dupixent's efficacy in managing CRSwNP.
Apart from this, GSK is another prominent company in the nasal polyps market. The company's biologic, mepolizumab (Nucala), targets interleukin-5 (IL-5) and is used for the treatment of severe eosinophilic asthma and has applications in CRSwNP. In July 2021, the FDA approved GSK’s Nucala (mepolizumab) for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). This approval is significant as Nucala became the first anti-IL-5 therapy approved for this condition in the United States. The decision was based on positive data from the pivotal SYNAPSE study, which demonstrated that Nucala significantly reduced the size of nasal polyps and the severity of nasal obstruction compared to placebo when added to standard care.
Request for customization: https://www.imarcgroup.com/request?type=report&id=7725&flag=E
Regional Analysis:
The major markets for nasal polyps include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for nasal polyps while also representing the biggest market for its treatment. This can be attributed to the increasing adoption of biologics, the adoption of minimally invasive surgical techniques, and the growing trend for personalized medicines.
Moreover, in March 2024, Xhance, developed by Optinose, received FDA approval for the treatment of chronic rhinosinusitis (with and without nasal polyps) in patients 18 years and older. This drug-device combination uses the Exhalation Delivery System™ to effectively deliver medication to hard-to-reach areas of the nasal cavity, improving symptoms and reducing inflammation. The approval was based on positive results from the ReOpen clinical program, which included significant improvements in symptoms and a reduction in sinus inflammation.
Besides this, The FDA has also approved Novartis's Xolair (omalizumab) for the treatment of adults with nasal polyps. Xolair is an injectable biologic that targets and blocks immunoglobulin E (IgE), reducing allergic inflammation. This new indication provides another option for patients with nasal polyps, particularly those who do not respond well to corticosteroids. The approval is supported by the POLYP 1 and POLYP 2 trials, which showed significant improvements in nasal polyp size and nasal congestion.
Key information covered in the report.
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
· United States
· Germany
· France
· United Kingdom
· Italy
· Spain
· Japan
Analysis Covered Across Each Country
· Historical, current, and future epidemiology scenario
· Historical, current, and future performance of the nasal polyps market
· Historical, current, and future performance of various therapeutic categories in the market
· Sales of various drugs across the nasal polyps market
· Reimbursement scenario in the market
· In-market and pipeline drugs
Competitive Landscape:
This report offers a comprehensive analysis of current nasal polyps marketed drugs and late-stage pipeline drugs.
In-Market Drugs
· Drug Overview
· Mechanism of Action
· Regulatory Status
· Clinical Trial Results
· Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
· Drug Overview
· Mechanism of Action
· Regulatory Status
· Clinical Trial Results
· Drug Uptake and Market Performance
Ask Our Expert & Browse Full Report with TOC & List of Figure: https://www.imarcgroup.com/nasal-polyps-market
IMARC Group Offer Other Reports:
Lymphangioleiomyomatosis Market: The 7 major lymphangioleiomyomatosis market reached a value of US$ 87.9 Million in 2023, and projected the 7MM to reach US$ 125.5 Million by 2034, exhibiting a growth rate (CAGR) of 3.29% during the forecast period from 2024 to 2034.
Palmar Hyperhidrosis Market: The 7 major palmar hyperhidrosis market reached a value of US$ 231.1 Million in 2023, and projected the 7MM to reach US$ 352.6 Million by 2034, exhibiting a growth rate (CAGR) of 3.92% during the forecast period from 2024 to 2034.
Primary Biliary Cholangitis Market: The 7 major primary biliary cholangitis market reached a value of US$ 510 Million in 2023, and projected the 7MM to reach US$ 1,200 Million by 2034, exhibiting a growth rate (CAGR) of 8.06% during the forecast period from 2024 to 2034.
Stress Urinary Incontinence Market: The 7 major stress urinary incontinence market is expected to exhibit a CAGR of 6.14% during the forecast period from 2024 to 2034.
Palmar Hyperhidrosis Market: The 7 major palmar hyperhidrosis market reached a value of US$ 231.1 Million in 2023, and projected the 7MM to reach US$ 352.6 Million by 2034, exhibiting a growth rate (CAGR) of 3.92% during the forecast period from 2024-2034.
T-Cell Non-Hodgkin Lymphoma Market: The 7 major T-cell non-hodgkin lymphoma market is expected to exhibit a CAGR of 5.55% during the forecast period from 2024-2034.
Pediatric Central Nervous System Tumors Market: The 7 major pediatric central nervous system tumors market is expected to exhibit a CAGR of 5.22% during the forecast period from 2024-2034.
Metastatic Prostate Cancer Market: The 7 major metastatic prostate cancer market is expected to exhibit a CAGR of 6.22% during the forecast period from 2024-2034.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800
The nasal polyps market size reached a value of USD 68.6 Million in 2023. Looking forward, the market is expected to reach USD 109.0 Million by 2034, exhibiting a growth rate (CAGR) of 4.3% during 2024-2034.
The market is driven by the increasing adoption of biologic therapies, such as dupilumab (Dupixent), the shift towards biologics, and the growing emphasis on minimally invasive surgical techniques. Additionally, there is an increasing focus on personalized medicine. Genetic and biomarker research is helping to identify patient subgroups that are more likely to respond to specific treatments, allowing for more tailored and effective management strategies.
Increasing Adoption of Biologic Therapies: Driving the Nasal Polyps Market
The nasal polyps market is experiencing a paradigm shift with the increasing adoption of biologic therapies. Biologics are advanced treatments derived from living organisms and are designed to target specific components of the immune system. This trend is primarily driven by the efficacy of these therapies in managing chronic rhinosinusitis with nasal polyps (CRSwNP), particularly in patients who do not respond adequately to conventional treatments such as corticosteroids. Moreover, one of the most significant biologics in this space is dupilumab (Dupixent), an interleukin-4 receptor alpha antagonist that inhibits the signaling of interleukins 4 and 13, key drivers of inflammation in CRSwNP. Clinical trials have demonstrated that dupilumab significantly reduces nasal polyp size, improves nasal congestion, and enhances overall quality of life. According to a study published in the Journal of Allergy and Clinical Immunology, patients treated with dupilumab showed a 57% reduction in nasal polyp score compared to placebo, along with marked improvements in symptoms and sinus opacification.
Request a PDF Sample Report: https://www.imarcgroup.com/nasal-polyps-market/requestsample
Additionally, the adoption of biologics is also fueled by their ability to reduce the need for surgery. Traditional treatments often involve repeated surgeries to remove polyps, which can be invasive and carry risks of complications. Biologics, by addressing the underlying inflammatory pathways, offer a non-surgical option that can maintain long-term control of symptoms. This is particularly important for patients with severe or recurrent polyps who face multiple surgeries throughout their lifetime. Furthermore, the approval of biologics by regulatory bodies like the FDA and EMA has provided a strong endorsement of their safety and efficacy. The FDA's approval of dupilumab for CRSwNP in 2019 marked a significant milestone, expanding the therapeutic options available to patients. This regulatory support has encouraged healthcare providers to incorporate biologics into their treatment regimens, further driving their adoption.
Advances in Minimally Invasive Surgical Techniques: Contributing to Market Expansion
The nasal polyps market is also witnessing significant advancements in minimally invasive surgical techniques. These innovations are reshaping the way nasal polyps are managed, offering patients less invasive options with shorter recovery times and fewer complications. Endoscopic sinus surgery (ESS) has become the gold standard for surgical intervention in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who do not respond to medical therapy. ESS involves the use of an endoscope to visualize the nasal passages and sinuses, allowing surgeons to remove polyps and other obstructions with high precision. The evolution of ESS has been marked by several technological advancements. High-definition cameras and advanced imaging systems provide surgeons with clear, detailed views of the sinus anatomy, enabling more accurate and effective surgeries. According to a review in the American Journal of Rhinology & Allergy, these technological improvements have significantly enhanced surgical outcomes, reducing the risk of complications and improving patient satisfaction.
Additionally, one of the notable innovations in minimally invasive surgery is balloon sinuplasty. This technique involves the insertion of a small balloon catheter into the sinus passage, which is then inflated to dilate the sinus openings. Balloon sinuplasty is particularly beneficial for patients with mild to moderate disease, as it is less invasive than traditional ESS and can be performed under local anesthesia. Studies have shown that balloon sinuplasty effectively improves sinus drainage and reduces symptoms with minimal discomfort and downtime. Another emerging trend is the integration of navigation systems and robotics in sinus surgery. Image-guided surgery (IGS) systems use preoperative CT scans to create a three-dimensional map of the patient's sinus anatomy, which guides the surgeon during the procedure. This technology enhances precision, especially in complex cases or in patients with distorted anatomy due to previous surgeries. Robotic-assisted surgery is also being explored to provide even greater control and accuracy. These innovations are expected to further reduce complications and improve surgical outcomes.
Emphasis on Personalized Medicine and Biomarker Research:
Personalized medicine and biomarker research are increasingly shaping the landscape of the nasal polyps market. This trend is driven by the recognition that chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous condition with diverse underlying mechanisms. Understanding the specific pathophysiological pathways involved in each patient can lead to more targeted and effective treatments, improving patient outcomes and reducing unnecessary interventions. Moreover, biomarker research has been instrumental in identifying distinct endotypes of CRSwNP. These endotypes are characterized by different inflammatory profiles, such as eosinophilic and non-eosinophilic types. Eosinophilic CRSwNP, which is marked by high levels of eosinophils, responds well to biologic therapies like dupilumab and mepolizumab that target specific cytokines involved in eosinophilic inflammation. By contrast, non-eosinophilic CRSwNP may require different therapeutic approaches.
Apart from this, advancements in diagnostic technologies are facilitating the identification of these biomarkers in clinical practice. Non-invasive tests that measure biomarker levels in nasal secretions or blood are becoming more accessible. For example, periostin, an extracellular matrix protein, has been identified as a potential biomarker for eosinophilic inflammation in CRSwNP. Elevated levels of periostin in nasal secretions can help clinicians identify patients who are likely to benefit from specific biologic therapies. Furthermore, the integration of biomarker research into clinical practice is enabling personalized treatment plans. Patients can be stratified based on their biomarker profiles, allowing for tailored therapy that targets the specific inflammatory pathways involved in their disease. This personalized approach not only enhances the efficacy of treatment but also minimizes adverse effects by avoiding unnecessary or ineffective therapies. Besides this, clinical trials are increasingly incorporating biomarker stratification to identify patient subgroups most likely to benefit from specific treatments. This approach is enhancing the precision of clinical research and accelerating the development of targeted therapies. For instance, trials investigating biologics for CRSwNP often include biomarker analysis to determine which patients exhibit the best response. Such stratified trials provide valuable insights into the efficacy and safety of new treatments across different patient populations.
Buy Full Report: https://www.imarcgroup.com/checkout?id=7725&method=587
Leading Companies in the Nasal Polyps Market:
The market research report by IMARC encompasses a comprehensive analysis of the competitive landscape in the market. Across the global nasal polyps market, several leading companies are at the forefront due to their significant contributions to the development and approval of new treatments. Some of the major players include Sanofi, Regeneron Pharmaceuticals, and GlaxoSmithKline (GSK). These companies lead the market through their innovative products, extensive research and development, and successful navigation of regulatory approvals.
Sanofi is a major player in the nasal polyps market, primarily due to its biologic therapy, dupilumab (Dupixent). Sanofi reported a robust second quarter in 2024, with a 29.2% increase in Dupixent sales, reaching €3,303 million. Dupixent's strong performance is pivotal in Sanofi's projected €13 billion target for 2024. The drug continues to gain traction across multiple indications, including chronic rhinosinusitis with nasal polyps (CRSwNP).
Regeneron Pharmaceuticals, in collaboration with Sanofi, announced positive outcomes from two pivotal Phase 3 trials, SINUS-24 and SINUS-52. These studies demonstrated that Dupixent significantly reduced nasal polyp size, nasal congestion severity, and the need for systemic corticosteroids and surgery. These findings were presented at the Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in San Francisco, highlighting Dupixent's efficacy in managing CRSwNP.
Apart from this, GSK is another prominent company in the nasal polyps market. The company's biologic, mepolizumab (Nucala), targets interleukin-5 (IL-5) and is used for the treatment of severe eosinophilic asthma and has applications in CRSwNP. In July 2021, the FDA approved GSK’s Nucala (mepolizumab) for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). This approval is significant as Nucala became the first anti-IL-5 therapy approved for this condition in the United States. The decision was based on positive data from the pivotal SYNAPSE study, which demonstrated that Nucala significantly reduced the size of nasal polyps and the severity of nasal obstruction compared to placebo when added to standard care.
Request for customization: https://www.imarcgroup.com/request?type=report&id=7725&flag=E
Regional Analysis:
The major markets for nasal polyps include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for nasal polyps while also representing the biggest market for its treatment. This can be attributed to the increasing adoption of biologics, the adoption of minimally invasive surgical techniques, and the growing trend for personalized medicines.
Moreover, in March 2024, Xhance, developed by Optinose, received FDA approval for the treatment of chronic rhinosinusitis (with and without nasal polyps) in patients 18 years and older. This drug-device combination uses the Exhalation Delivery System™ to effectively deliver medication to hard-to-reach areas of the nasal cavity, improving symptoms and reducing inflammation. The approval was based on positive results from the ReOpen clinical program, which included significant improvements in symptoms and a reduction in sinus inflammation.
Besides this, The FDA has also approved Novartis's Xolair (omalizumab) for the treatment of adults with nasal polyps. Xolair is an injectable biologic that targets and blocks immunoglobulin E (IgE), reducing allergic inflammation. This new indication provides another option for patients with nasal polyps, particularly those who do not respond well to corticosteroids. The approval is supported by the POLYP 1 and POLYP 2 trials, which showed significant improvements in nasal polyp size and nasal congestion.
Key information covered in the report.
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
· United States
· Germany
· France
· United Kingdom
· Italy
· Spain
· Japan
Analysis Covered Across Each Country
· Historical, current, and future epidemiology scenario
· Historical, current, and future performance of the nasal polyps market
· Historical, current, and future performance of various therapeutic categories in the market
· Sales of various drugs across the nasal polyps market
· Reimbursement scenario in the market
· In-market and pipeline drugs
Competitive Landscape:
This report offers a comprehensive analysis of current nasal polyps marketed drugs and late-stage pipeline drugs.
In-Market Drugs
· Drug Overview
· Mechanism of Action
· Regulatory Status
· Clinical Trial Results
· Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
· Drug Overview
· Mechanism of Action
· Regulatory Status
· Clinical Trial Results
· Drug Uptake and Market Performance
Ask Our Expert & Browse Full Report with TOC & List of Figure: https://www.imarcgroup.com/nasal-polyps-market
IMARC Group Offer Other Reports:
Lymphangioleiomyomatosis Market: The 7 major lymphangioleiomyomatosis market reached a value of US$ 87.9 Million in 2023, and projected the 7MM to reach US$ 125.5 Million by 2034, exhibiting a growth rate (CAGR) of 3.29% during the forecast period from 2024 to 2034.
Palmar Hyperhidrosis Market: The 7 major palmar hyperhidrosis market reached a value of US$ 231.1 Million in 2023, and projected the 7MM to reach US$ 352.6 Million by 2034, exhibiting a growth rate (CAGR) of 3.92% during the forecast period from 2024 to 2034.
Primary Biliary Cholangitis Market: The 7 major primary biliary cholangitis market reached a value of US$ 510 Million in 2023, and projected the 7MM to reach US$ 1,200 Million by 2034, exhibiting a growth rate (CAGR) of 8.06% during the forecast period from 2024 to 2034.
Stress Urinary Incontinence Market: The 7 major stress urinary incontinence market is expected to exhibit a CAGR of 6.14% during the forecast period from 2024 to 2034.
Palmar Hyperhidrosis Market: The 7 major palmar hyperhidrosis market reached a value of US$ 231.1 Million in 2023, and projected the 7MM to reach US$ 352.6 Million by 2034, exhibiting a growth rate (CAGR) of 3.92% during the forecast period from 2024-2034.
T-Cell Non-Hodgkin Lymphoma Market: The 7 major T-cell non-hodgkin lymphoma market is expected to exhibit a CAGR of 5.55% during the forecast period from 2024-2034.
Pediatric Central Nervous System Tumors Market: The 7 major pediatric central nervous system tumors market is expected to exhibit a CAGR of 5.22% during the forecast period from 2024-2034.
Metastatic Prostate Cancer Market: The 7 major metastatic prostate cancer market is expected to exhibit a CAGR of 6.22% during the forecast period from 2024-2034.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800
